Andrew D Wiese1, Marie R Griffin2, Yuwei Zhu3, Edward F Mitchel4, Carlos G Grijalva5. 1. Department of Health Policy, Vanderbilt University, Nashville, USA. Electronic address: andrew.d.wiese@vanderbilt.edu. 2. Department of Health Policy, Vanderbilt University, Nashville, USA; Department of Medicine, Vanderbilt University, Nashville, USA; VA TN Valley Health Care System, Nashville, USA. 3. Department of Biostatistics, Vanderbilt University, Nashville, USA. 4. Department of Health Policy, Vanderbilt University, Nashville, USA. 5. Department of Health Policy, Vanderbilt University, Nashville, USA; VA TN Valley Health Care System, Nashville, USA.
Abstract
BACKGROUND: Parapneumonic empyema, a serious complication of pneumonia, started increasing among U.S. children before the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in 2000, and continued afterwards. This increase was due in part to pneumococcal serotypes not included in PCV7 that were included in the new 13-valent (PCV13) vaccine introduced in 2010. We assessed changes in the incidence of empyema hospitalizations among U.S. children after PCV13 introduction. METHODS: We calculated annualized empyema hospitalization rates among U.S. children <18years using Nationwide Inpatient Sample and Census data (1997-2013) for four periods based on PCV7 and PCV13 introductions. Relative rates (RR) and 95% confidence intervals (CI) were calculated by age group and sex, comparing PCV7 [early-PCV7 (2001-2005) and late-PCV7 (2006-2009)] and PCV13 (2011-2013) periods with the pre-PCV7 period (1997-1999). Secondary analyses examined changes in pneumococcal, streptococcal, staphylococcal and unspecified empyema. RESULTS: Among children <18years of age, annualized empyema hospitalization rates peaked at 3.6 per 100,000 in the late-PCV7 period compared with 2.1 per 100,000 in the pre-PCV7 period [RR: 1.70 (95% CI: 1.11-2.60)]. However, annualized rates in the post-PCV13 period declined to 2.0 per 100,000, similar to rates in the pre-PCV7 period. Empyema rates among children <2years were lower in the post-PCV13 period compared to the pre-PCV7 period [RR: 0.77 (95% CI: 0.61-0.96)], but rates in the two periods among children 2-4 and 5-17years were similar. Most empyema were of unspecified etiology. Pneumococcal and unspecified empyema declined after PCV13 introduction. CONCLUSIONS: Although empyema hospitalization rates among U.S. children peaked after PCV7 introduction, rates decreased substantially following the introduction of PCV13. Copyright Â
BACKGROUND:Parapneumonic empyema, a serious complication of pneumonia, started increasing among U.S. children before the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in 2000, and continued afterwards. This increase was due in part to pneumococcal serotypes not included in PCV7 that were included in the new 13-valent (PCV13) vaccine introduced in 2010. We assessed changes in the incidence of empyema hospitalizations among U.S. children after PCV13 introduction. METHODS: We calculated annualized empyema hospitalization rates among U.S. children <18years using Nationwide Inpatient Sample and Census data (1997-2013) for four periods based on PCV7 and PCV13 introductions. Relative rates (RR) and 95% confidence intervals (CI) were calculated by age group and sex, comparing PCV7 [early-PCV7 (2001-2005) and late-PCV7 (2006-2009)] and PCV13 (2011-2013) periods with the pre-PCV7 period (1997-1999). Secondary analyses examined changes in pneumococcal, streptococcal, staphylococcal and unspecifiedempyema. RESULTS: Among children <18years of age, annualized empyema hospitalization rates peaked at 3.6 per 100,000 in the late-PCV7 period compared with 2.1 per 100,000 in the pre-PCV7 period [RR: 1.70 (95% CI: 1.11-2.60)]. However, annualized rates in the post-PCV13 period declined to 2.0 per 100,000, similar to rates in the pre-PCV7 period. Empyema rates among children <2years were lower in the post-PCV13 period compared to the pre-PCV7 period [RR: 0.77 (95% CI: 0.61-0.96)], but rates in the two periods among children 2-4 and 5-17years were similar. Most empyema were of unspecified etiology. Pneumococcal and unspecifiedempyema declined after PCV13 introduction. CONCLUSIONS: Although empyema hospitalization rates among U.S. children peaked after PCV7 introduction, rates decreased substantially following the introduction of PCV13. Copyright Â
Authors: Krow Ampofo; Andrew T Pavia; Chris R Stockmann; Anne J Blaschke; Hsin Yi Cindy Weng; Kent E Korgenski; Judy Daly; Carrie L Byington Journal: Pediatr Infect Dis J Date: 2011-12 Impact factor: 2.129
Authors: Holly A Hill; Laurie D Elam-Evans; David Yankey; James A Singleton; Maureen Kolasa Journal: MMWR Morb Mortal Wkly Rep Date: 2015-08-28 Impact factor: 17.586
Authors: Andrea C Farnham; Christopher M Zimmerman; Vikki Papadouka; Kevin J Konty; Jane R Zucker; Geetha V Nattanmai; Sherly Jose; Jennifer B Rosen Journal: JAMA Pediatr Date: 2015-07 Impact factor: 16.193
Authors: Michael Harris; Julia Clark; Nicky Coote; Penny Fletcher; Anthony Harnden; Michael McKean; Anne Thomson Journal: Thorax Date: 2011-10 Impact factor: 9.139
Authors: Allison E Curry; Michael R Elliott; Melissa R Pfeiffer; Konny H Kim; Dennis R Durbin Journal: Am J Prev Med Date: 2014-11-03 Impact factor: 5.043
Authors: Matthew F Thomas; Carmen L Sheppard; Malcolm Guiver; Mary P E Slack; Robert C George; Russell Gorton; James Y Paton; Clare Simmister; David Cliff; Mohamed A Elemraid; Julia E Clark; Stephen P Rushton; David Anthony Spencer Journal: Arch Dis Child Date: 2012-10-16 Impact factor: 3.791
Authors: Sonia Saxena; Christina Atchison; Elizabeth Cecil; Mike Sharland; Elizabeth Koshy; Alex Bottle Journal: J Infect Date: 2015-07-06 Impact factor: 6.072
Authors: Marien I de Jonge; Amelieke J H Cremers; Daan W Arends; Wynand Alkema; Indri Hapsari Putri; Christa E van der Gaast-de Jongh; Marc Eleveld; Jeroen D Langereis; Quirijn de Mast; Jacques F Meis Journal: Microbiol Spectr Date: 2022-06-09
Authors: Catarina Silva-Costa; Maria João Brito; Marcos D Pinho; Ana Friães; Sandra I Aguiar; M Ramirez; Jose Melo-Cristino Journal: Emerg Infect Dis Date: 2018-07 Impact factor: 6.883